Adriamycin in Patients with Liver Cancer
Author Information
Author(s): P.J. Johnson, N. Dobbs, C. Kalayci, M.C. Aldous, P. Harper, E.M. Metivier, R. Williams
Primary Institution: Institute of Liver Studies, King's College Hospital School of Medicine and Dentistry
Hypothesis
How do patients with hepatocellular carcinoma and moderate hyperbilirubinaemia tolerate a standard dose of Adriamycin?
Conclusion
Hyperbilirubinaemic patients may tolerate a full dose of Adriamycin, but the response rate remains disappointingly low at only 18%.
Supporting Evidence
- Hyperbilirubinaemic patients experienced marked myelosuppression but only minor side effects.
- The area under the concentration-time curve was significantly greater for both Adriamycin and adriamycinol in hyperbilirubinaemic patients.
- Response rate was disappointingly low at only 18%.
Takeaway
Doctors gave a medicine called Adriamycin to sick patients with liver cancer to see if it would help them, but it didn't work very well.
Methodology
30 patients with inoperable hepatocellular carcinoma were treated with a standard dose of Adriamycin, and their responses and side effects were monitored.
Limitations
The number of evaluable patients was too small to make confident statements about the regimen's influence on response or survival rate.
Participant Demographics
Patients included both men and women from various nationalities, with a mix of cirrhosis and non-cirrhosis cases.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website